TOP RANKED ROSEN LAW FIRM Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – EW

Core Points - Rosen Law Firm is reminding investors who purchased Edwards Lifesciences Corporation securities between February 6, 2024, and July 24, 2024, of the December 13, 2024, lead plaintiff deadline for a class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must act by December 13, 2024, to serve as lead plaintiff [3] Case Details - The lawsuit alleges that during the class period, defendants provided misleading information regarding Edwards' expected revenue for fiscal year 2024, particularly concerning the growth of its Transcatheter Aortic Valve Replacement (TAVR) product [5] - Defendants made claims about strong commitment to the TAVR platform and significant demand in lower-penetrated markets, which, when proven false, resulted in investor damages [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions, as many firms may not have the necessary experience or resources [4] - Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]